Med BioGene Announces Financing

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 7, 2008) - Med BioGene Inc. (TSX VENTURE:MBI), a life science company focused on the development and commercialization of genomic-based diagnostic tests for cancer and cardiovascular disease, announces that it has filed a preliminary short form prospectus in respect of a public offering (the "Offering") of units (the "Units") for gross proceeds of between $1 million and $3 million. A copy of the preliminary short form prospectus can be found at www.sedar.com.